Lupin Introduces Loteprednol Etabonate Ophthalmic Suspension in the US Market

Lupin has launched loteprednol etabonate ophthalmic suspension in the US, expanding its ophthalmology portfolio. The product is used to treat inflammation and pain following eye surgeries. Lupin's entry into the US market marks a significant milestone in its growth strategy, highlighting its commitment to providing high-quality medicines to patients worldwide.

Lupin Limited, a global pharmaceutical major, has announced the launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5% in the United States on July 16, 2025. This launch represents a significant milestone in Lupin's growth strategy and underscores its commitment to providing affordable treatment options in key markets.

The product is a generic version of Lotemax® Ophthalmic Suspension, 0.5% by Bausch & Lomb Inc., which recorded annual sales of approximately USD 55 million in the U.S. as of May 2025 [1]. The generic version is indicated for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, as well as post-operative inflammation following ocular surgery. This launch strengthens Lupin's U.S. portfolio in the ophthalmic therapy area.

Lupin continues to maintain its strong presence in the U.S. generics space while also focusing on complex generics, biotechnology products, and branded formulations globally. The company's entry into the U.S. market for this specific product marks a strategic move to expand its reach and offer more affordable treatment options for patients.

References:
[1] https://www.businessupturn.com/business/corporates/lupin-launches-generic-lotemax-ophthalmic-suspension-in-the-u-s-market/